• Radicicol Hsp90 Inhibitor: Practical Assay Workflows

  2026-09-30

  Radicicol is a versatile Hsp90 inhibitor for connecting chaperone biology with adipocyte differentiation, ovarian carcinoma apoptosis, kinase biochemistry, and inflammatory models. This guide translates the compound’s documented activity into practical workflows, controls, optimization steps, and a cautious strategy for testing Hsp90 dependence in antigen cross-presentation.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages

  2026-09-30

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that accumulates in macrophage lysosomes and activates AMPKα through GPR155–mTORC1 signaling. The study links this pathway to STAT6 phosphorylation, ARG1 production, immunosuppressive tumor-associated macrophages, and reduced response to anti-PD-1 therapy.

• Netarsudil and the Next Codelivery Frontier

  2026-09-29

  Netarsudil (AR-13324) links validated ROCK biology in the trabecular meshwork with an emerging nanoparticle strategy for siRNA codelivery. This translational analysis separates established ocular mechanism from preclinical formulation opportunity and outlines a practical path for rigorous validation.

• U0126-EtOH: MEK1/2 Inhibitor Workflows

  2026-09-29

  U0126-EtOH enables controlled MEK1/2 inhibition for neuronal oxidative-stress assays, inflammatory models, and pathway-dissection studies. This practical guide connects mechanism, workflow design, assay controls, and troubleshooting while distinguishing ERK1/2 effects from ERK5 biology.

• Viral RIPK3 Degradation and Necroptosis Control

  2026-09-28

  Liu et al. identified a viral inducer of RIPK3 degradation, or vIRD, that co-opts host SCF ubiquitin-ligase machinery to suppress necroptosis. Their genetic, biochemical, virological, and mouse studies connect vIRD-dependent RIPK3 loss with orthopoxvirus replication, inflammation, and disease severity.

• JNK-IN-7 for Apoptosis and MAPK Signaling Studies

  2026-09-28

  Use JNK-IN-7 to test whether JNK activity contributes to infection-triggered c-Jun phosphorylation, apoptosis, and inflammatory signaling—not to assume those outcomes from pathway association alone. A phase-resolved Candida krusei model offers a practical framework for pairing inhibitor perturbation with target-engagement and cell-death readouts.

• Dual SORT LNPs Enable Liver–Lung Base Editing

  2026-09-27

  This study develops paired Selective ORgan-Targeting lipid nanoparticles to deliver base-editing therapy to both liver and lung cells in an alpha-1 antitrypsin deficiency model. The results suggest that organ-directed delivery can address disease mechanisms in multiple tissues, while highlighting the need to evaluate durability, safety, and translation beyond the study model.

• BRD4770: A G9a Histone Methyltransferase Inhibitor

  2026-09-26

  Use BRD4770 to investigate how G9a inhibition, reduced H3K9 methylation, and senescence relate to cancer-cell growth. This guide pairs a PANC-1 workflow with practical safeguards for a key experimental constraint: the compound is reported insoluble in common laboratory solvents.

• ARID1A Loss Rewires Melanoma Drug-Response Networks

  2026-09-25

  The study integrates molecular data to compare early responses to BRAF/MAPK inhibition in a BRAF V600E-sensitive melanoma model and an ARID1A-knockout resistant derivative. It identifies altered MAPK, JNK, PRKD1, JUN, and immune-associated networks, offering testable hypotheses for resistance research while emphasizing that candidate network nodes require further validation.

• ATRX Loss Sensitizes Glioma Cells to PDGFR Inhibitors

  2026-09-25

  Pladevall-Morera and colleagues found that ATRX-deficient high-grade glioma cells are more sensitive to selected receptor tyrosine kinase and PDGFR inhibitors, and that combining RTK inhibition with temozolomide increased cellular toxicity. The study supports evaluating ATRX status when interpreting inhibitor responses, while its cell-based findings do not establish clinical efficacy or sensitivity to every PDGFR inhibitor.

• SIS3 in SMAD3-Dependent Cancer Assays

  2026-09-24

  Learn how SIS3, a selective Smad3 inhibitor, can help test pathway dependence in enhancer-driven lung adenocarcinoma models. This article connects the LINC01977–TGF-β/SMAD3 feedback loop to practical assay design while clarifying what the available evidence does—and does not—show.

• PKM2 inhibitor (compound 3k): Reading the Context

  2026-09-24

  PKM2 inhibitor (compound 3k) connects cancer metabolism research with macrophage immunometabolism, but its effects depend on biological context. This guide interprets the evidence and shows how to design experiments that distinguish metabolic changes from cell-specific outcomes.

• DGLA-Driven Ferroptosis in AML: ACSL4’s Role

  2026-09-23

  This study identifies exogenous dihomo-γ-linolenic acid (DGLA) as a lipid-metabolism input that can sensitize acute myeloid leukemia (AML) cells to ferroptosis, with ACSL4 required for much of the observed effect. The findings connect fatty-acid remodeling to ferroptosis susceptibility in preclinical models, while leaving dose, safety, and clinical efficacy questions unresolved.

• SM-164 Workflow for IAP-Driven Apoptosis

  2026-09-23

  SM-164 provides a rapid, mechanistically traceable route from IAP engagement to TNFα-dependent apoptosis and caspase activation in tumor-cell models. This workflow combines target-engagement kinetics, orthogonal death readouts, and RNA Pol II-informed assay design to distinguish active signaling from nonspecific loss of viability.

• Thioguanine Workflows for Cancer and Viral Assays

  2026-09-22

  Thioguanine and 6-thioguanine support coordinated cancer-cell, epigenetic, and EV71 research workflows when exposure, solubility, and cell-health controls are handled carefully. This guide translates product performance data and a modern lymphoma trial design into practical assay choices without conflating valemetostat findings with thioguanine activity.

743 records 3/50 page Previous Next 12345 下5页 Last page